NEW YORK--(BUSINESS WIRE)--The law firm of Wohl & Fruchter LLP is investigating possible violations of federal securities laws by officers and directors of GTX Inc. (GTX) (NASDAQ: GTXI).
On August 19, 2013, GTX announced that enobosarm, its potential treatment for muscle wasting in lung cancer patients, fell short of key goals agreed upon with the Food and Drug Administration in two phase III clinical trials in terms of increasing lean body mass and improving physical function.
Upon the above news, GTX shares have declined over 60% in trading on August 19, 2013.
Wohl & Fruchter’s investigation concerns whether GTX management improperly concealed from investors, among other things, that past clinical studies were deeply flawed, and thus the latest phase III trials were likely to fail.
Persons with relevant information, and GTXI shareholders with questions about this investigation, are invited to contact the attorney below, or our Firm by calling 866.833.6245.
Additional information is available on our website at: http://www.wohlfruchter.com/cases/gtxi.
About Wohl & Fruchter
Wohl & Fruchter LLP represents plaintiffs in litigation arising from fraud and other fiduciary breaches by corporate managers, as well as other complex litigation matters. Please visit our website, www.wohlfruchter.com, to learn more about our Firm, or contact one of our partners.
This release may be deemed to constitute attorney advertising.